|
業務類別
|
Biotechnology |
|
業務概覽
|
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug. |
| 公司地址
| 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065 |
| 電話號碼
| +1 650 649-3530 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.coherus.com |
| 員工數量
| 228 |
| Mr. Bryan J. McMichael |
Chief Financial Officer and Principal Accounting Officer |
美元 467.77K |
29/04/2025 |
| Mr. Dennis M. Lanfear |
President, Chief Executive Officer and Chairman of the Board |
美元 1.01M |
29/04/2025 |
|
|
| Ms. Rita A. Karachun |
Director |
29/04/2025 |
| Dr. Jill O’Donnell-Tormey |
Independent Director |
29/04/2025 |
| Mr. Charles W. Newton |
Independent Director |
29/04/2025 |
| Dr. Lee N. Newcomer, M.D. |
Independent Director |
29/04/2025 |
| Mr. Ali J. Satvat |
Independent Director |
29/04/2025 |
| Mr. Mats L. Wahlstrom |
Lead Independent Director |
29/04/2025 |
| Mr. Dennis M. Lanfear |
President, Chief Executive Officer and Chairman of the Board |
29/04/2025 |
| Ms. Georgia L. Erbez |
Director |
29/04/2025 |
| Dr. Michael Ryan, Pharm.D. |
Director |
29/04/2025 |
|
|
|
|
